308 related articles for article (PubMed ID: 24026863)
1. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species.
Drgona L; Khachatryan A; Stephens J; Charbonneau C; Kantecki M; Haider S; Barnes R
Eur J Clin Microbiol Infect Dis; 2014 Jan; 33(1):7-21. PubMed ID: 24026863
[TBL] [Abstract][Full Text] [Related]
2. The changing face of epidemiology of invasive fungal disease in Europe.
Lass-Flörl C
Mycoses; 2009 May; 52(3):197-205. PubMed ID: 19391253
[TBL] [Abstract][Full Text] [Related]
3. Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia.
Schmiedel Y; Zimmerli S
Swiss Med Wkly; 2016; 146():w14281. PubMed ID: 26901377
[TBL] [Abstract][Full Text] [Related]
4. Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy.
Mikolajewska A; Schwartz S; Ruhnke M
Mycoses; 2012 Jan; 55(1):2-16. PubMed ID: 21554421
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients: which is better for whom?
Leather HL; Wingard JR
Curr Opin Infect Dis; 2002 Aug; 15(4):369-75. PubMed ID: 12130932
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B.
Lacerda JF; Oliveira CM
Clin Drug Investig; 2013 Feb; 33 Suppl 1():S5-14. PubMed ID: 23381977
[TBL] [Abstract][Full Text] [Related]
7. The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).
Lortholary O; Fernández-Ruiz M; Perfect JR
J Antimicrob Chemother; 2016 Nov; 71(suppl 2):ii31-ii36. PubMed ID: 27880667
[TBL] [Abstract][Full Text] [Related]
8. Molecular assay to detect nosocomial fungal infections in intensive care units.
Badiee P; Alborzi A; Joukar M
Eur J Intern Med; 2011 Dec; 22(6):611-5. PubMed ID: 22075290
[TBL] [Abstract][Full Text] [Related]
9. Burden of hospitalization of patients with Candida and Aspergillus infections in Australia.
Slavin M; Fastenau J; Sukarom I; Mavros P; Crowley S; Gerth WC
Int J Infect Dis; 2004 Mar; 8(2):111-20. PubMed ID: 14732329
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of invasive fungal infection.
Castón-Osorio JJ; Rivero A; Torre-Cisneros J
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S103-9. PubMed ID: 19013332
[TBL] [Abstract][Full Text] [Related]
11. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients.
Hamza NS; Ghannoum MA; Lazarus HM
Bone Marrow Transplant; 2004 Sep; 34(5):377-89. PubMed ID: 15247928
[TBL] [Abstract][Full Text] [Related]
12. Patients at high risk of invasive fungal infections: when and how to treat.
Rüping MJ; Vehreschild JJ; Cornely OA
Drugs; 2008; 68(14):1941-62. PubMed ID: 18778118
[TBL] [Abstract][Full Text] [Related]
13. Update on antifungal treatment of invasive Candida and Aspergillus infections.
Maschmeyer G; Ruhnke M
Mycoses; 2004 Aug; 47(7):263-76. PubMed ID: 15310328
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient.
Garnacho-Montero J; Olaechea P; Alvarez-Lerma F; Alvarez-Rocha L; Blanquer J; Galván B; Rodriguez A; Zaragoza R; Aguado JM; Mensa J; Solé A; Barberán J
Rev Esp Quimioter; 2013 Jun; 26(2):173-88. PubMed ID: 23817660
[TBL] [Abstract][Full Text] [Related]
15. Active Surveillance Program to Increase Awareness on Invasive Fungal Diseases: the French RESSIF Network (2012 to 2018).
Bretagne S; Sitbon K; Desnos-Ollivier M; Garcia-Hermoso D; Letscher-Bru V; Cassaing S; Millon L; Morio F; Gangneux JP; Hasseine L; Favennec L; Cateau E; Bailly E; Moniot M; Bonhomme J; Desbois-Nogard N; Chouaki T; Paugam A; Bouteille B; Pihet M; Dalle F; Eloy O; Sasso M; Demar M; Mariani-Kurkdjian P; Robert V; Lortholary O; Dromer F;
mBio; 2022 Jun; 13(3):e0092022. PubMed ID: 35499498
[TBL] [Abstract][Full Text] [Related]
16. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.
Segal BH; Herbrecht R; Stevens DA; Ostrosky-Zeichner L; Sobel J; Viscoli C; Walsh TJ; Maertens J; Patterson TF; Perfect JR; Dupont B; Wingard JR; Calandra T; Kauffman CA; Graybill JR; Baden LR; Pappas PG; Bennett JE; Kontoyiannis DP; Cordonnier C; Viviani MA; Bille J; Almyroudis NG; Wheat LJ; Graninger W; Bow EJ; Holland SM; Kullberg BJ; Dismukes WE; De Pauw BE
Clin Infect Dis; 2008 Sep; 47(5):674-83. PubMed ID: 18637757
[TBL] [Abstract][Full Text] [Related]
17. Fungal Infections of the Central Nervous System in Children.
McCarthy MW; Kalasauskas D; Petraitis V; Petraitiene R; Walsh TJ
J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e123-e133. PubMed ID: 28903523
[TBL] [Abstract][Full Text] [Related]
18. Invasive fungal infections in solid organ transplant recipients.
Shoham S; Marr KA
Future Microbiol; 2012 May; 7(5):639-55. PubMed ID: 22568718
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of otomycosis in outpatient department of otolaryngology in Tribhuvan University Teaching Hospital, Kathmandu, Nepal.
Pradhan B; Tuladhar NR; Amatya RM
Ann Otol Rhinol Laryngol; 2003 Apr; 112(4):384-7. PubMed ID: 12731637
[TBL] [Abstract][Full Text] [Related]
20. Update on antifungal resistance in Aspergillus and Candida.
Arendrup MC
Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():42-8. PubMed ID: 24372701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
